GenScript invests $15M in Singapore facility

GenScript Biotech Corporation has announced the opening of a new facility for highly automated protein and gene preparation services, with $15 million investment. Supported by the Singapore’s Economic Development Board (EDB), the new production site will support the Asia Pacific region and complements the current production sites in the United States and China. The new manufacturing facility occupies over 30,000 square feet space at Solaris@Kallang building. The cutting edge facility in Singapore features a high throughput platform and proprietary technology of GenScript’s protein production to provide higher yield with a shorter turnaround time. The capacity of the new facility could also be expanded to strengthen other business units to support cell and gene therapy and vaccine development in the region. In addition, GenScript and A*STAR Diagnostics Development Hub have signed a memorandum of understanding (MoU) to explore the possibility of collaborations for the purposes of building manufacturing capabilities in Singapore.